Related Experiment Video
Updated: Jun 6, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Kras in metastatic colorectal cancer
Andreas Wicki1, Richard Herrmann, Gerhard Christofori
1Albert-Ludwigs University, University Medical Center Freiburg, Dept. of Hematology and Oncology, Hugstetterstraße 55, 79106 Freiburg, DE. andreas.wicki@uniklinik-freiburg.de
Abstract:
Kras, a small intracellular GTPase, is a central intermediary of the epidermal growth factor receptor (EGFR) and other tyrosine kinase receptor pathways. Increased EGFR and Kras signalling is involved in colorectal carcinogenesis and tumour progression. Mutations of Kras result in the loss of its GTPase activity and thus in a constitutive activation of Kras signalling. Kras mutations are found in 30-60% of colorectal cancers. The concordance between Kras mutations in the primary tumour and related metastatic sites is high. Since mutation of Kras confers resistance to anti-EGFR-antibody therapy, it is critical to assess Kras mutational status in colorectal cancer patients. Anti-EGFR-antibody therapy improves survival in patients with metastatic colorectal cancer and wild-type Kras.
Insights
Kras mutations are common in colorectal cancer and lead to resistance against anti-EGFR antibody therapy. Testing Kras status is crucial for effective treatment of metastatic colorectal cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Kras is a key signaling intermediate in epidermal growth factor receptor (EGFR) pathways.
- Aberrant EGFR and Kras signaling drives colorectal cancer development and progression.
- Kras mutations lead to constitutive pathway activation, impacting cancer cell behavior.
Purpose of the Study:
- To highlight the significance of Kras mutational status in colorectal cancer.
- To underscore the role of Kras mutations in conferring resistance to anti-EGFR antibody therapy.
- To emphasize the clinical importance of assessing Kras status for treatment selection.
Main Methods:
- Analysis of Kras mutational status in colorectal cancer.
- Review of the impact of Kras mutations on therapeutic response.
- Correlation of Kras mutations between primary tumors and metastatic sites.
Main Results:
- Kras mutations are prevalent in 30-60% of colorectal cancers.
- Kras mutations result in constitutive Kras signaling due to loss of GTPase activity.
- High concordance of Kras mutations observed between primary and metastatic colorectal tumors.
- Kras mutations confer resistance to anti-EGFR antibody therapies.
Conclusions:
- Assessing Kras mutational status is critical for managing colorectal cancer patients.
- Accurate Kras testing guides the selection of anti-EGFR antibody therapy.
- Treatment decisions for metastatic colorectal cancer should incorporate Kras mutation data.
